Biogen Inc.

AI Score

0

Unlock

143.00
-7.18 (-4.78%)
At close: Jan 14, 2025, 8:58 PM
143.08
0.05%
After-hours Jan 14, 2025, 07:00 PM EST
undefined%
Bid 143
Market Cap 20.84B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 11.05
PE Ratio (ttm) 12.94
Forward PE n/a
Analyst Hold
Ask 143.33
Volume 1,390,315
Avg. Volume (20D) 1,498,347
Open 149.92
Previous Close 150.18
Day's Range 142.42 - 150.22
52-Week Range 142.42 - 252.17
Beta undefined

About BIIB

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an ad...

Sector Healthcare
IPO Date Sep 17, 1991
Employees 7,570
Stock Exchange NASDAQ
Ticker Symbol BIIB

Analyst Forecast

According to 25 analyst ratings, the average rating for BIIB stock is "Hold." The 12-month stock price forecast is $210, which is an increase of 46.85% from the latest price.

Buy 44.00%
Hold 52.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Biogen Inc. is scheduled to release its earnings on Feb 11, 2025, before market opens.
Analysts project revenue of $2.42B, reflecting a 1.42% YoY growth and earnings per share of 3.44, making a 16.61% increase YoY.
1 month ago · Source
-1.28%
Biogen shares are trading lower after Needham down... Unlock content with Pro Subscription
5 months ago · Source
-3.53%
Biogen shares are trading lower after Needham and Truist Securities lowered their respective price targets on the stock.